Zeo ScientifiX, Inc.

On January 26, 2026, Neurovive Holding Co., LLC (“Neurovive”), Paragon Medical Group, LLC (“Paragon”), and Dr. David Buechner (“Dr. Buechner,” and together with Neurovive and Paragon, “Plaintiffs”), filed a complaint in the Circuit Court of Benton County, Arkansas Civil Division against the Company asserting claims for breach of contract, breach of fiduciary duty, misappropriation of trade secrets, fraud, promissory estoppel, unjust enrichment and conversion (“Complaint”). The Company removed the state court case to the United States District Court for the Western District of Arkansas. Plaintiffs are seeking preliminary and permanent injunctive relief and compensatory damages in an unspecified amount. The litigation arises from a prior arrangement between Plaintiffs and the Company relating to a proposed clinical trial and associated funding obligations. The parties dispute the circumstances under which the arrangement was terminated. The Company’s disputes all allegations in the Complaint and intends to vigorously defend the action. At this early stage of the proceedings, the Company is unable to predict the ultimate outcome of the litigation.

In addition to the above and to matters which have been resolved as reported in previous periodic reports filed under the Securities Exchange Act of 1934, as amended, from time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in any such matter may harm our business.